BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. is pleased to announce that Thomas W. Dubensky, Chief Scientific Officer, and Peter Lauer, Director of Molecular Biology, have been selected to deliver oral presentations at the Immunological Mechanisms of Vaccination meeting, which is taking place from December 13-18 in Ottawa, Canada.
Dr. Dubensky is scheduled to present on Friday, December 14. His presentation is entitled, “Development of Cyclic Dinucleotides (CDNs) as STING-Targeted Molecular Adjuvants.” Dr. Lauer is scheduled to present on Sunday, December 16. His presentation is entitled, “Recombinase-Induced Intracellular Death (Lm-RIID): A Novel, Safe, and Potent L. Monocytogenes Vaccine Platform.”
About Aduro BioTech, Inc.
Aduro is advancing multiple therapeutic and prophylactic vaccines for cancer and infectious diseases based on its proprietary attenuated Listeria monocytogenes vaccine platforms. The company is also advancing a new program towards clinical evaluation that utilizes targeted small molecule immune modulators that have broad application for vaccine design. The company's Listeria platform has been validated by 26 publications that illustrate the platform's unique combination of safety and potency, and the platform has received more than $24 million in federal and private grant and contract funding. In addition, the company has multiple patents issued in the U.S., Europe and throughout the world that broadly protect its proprietary and clinical applications. The company’s lead therapeutic, CRS-207, is currently being evaluated in a randomized, controlled Phase 2 trial in patients with metastatic pancreatic cancer, in which enrollment has completed, and a Phase 1B clinical trial in patients with malignant pleural mesothelioma, in which enrollment is ongoing.